Quantitative Secretome Analysis Reveals Clinical Values of Carbonic Anhydrase II in Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

Quantitative Secretome Analysis Reveals Clinical Values of Carbonic Anhydrase II in Hepatocellular Carcinoma

Published:2021-02 Issue:1 Volume:19 Page:94-107
ISSN:1672-0229
Container-title:Genomics, Proteomics & Bioinformatics
language:en
Short-container-title:Genomics, Proteomics & Bioinformatics

Author:

Xing Xiaohua^ORCID,Yuan Hui^ORCID,Liu Hongzhi^ORCID,Tan Xionghong^ORCID,Zhao Bixing^ORCID,Wang Yingchao^ORCID,Ouyang Jiahe^ORCID,Lin Minjie^ORCID,Liu Xiaolong^ORCID,Huang Aimin^ORCID

Funder

Fujian Provincial Natural Science Foundation

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Computational Mathematics,Genetics,Molecular Biology,Biochemistry

Reference47 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

2. The global burden of liver disease: the major impact of China;Wang;Hepatology,2014

3. Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma;Zhou;Cancer,2001

4. Prognostic determinants for survival after resection/ablation of a large hepatocellular carcinoma;Ng;HPB (Oxford),2009

5. Subcellular tissue proteomics of hepatocellular carcinoma for molecular signature discovery;Lee;J Proteome Res,2011

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proteomics-driven noninvasive screening of circulating serum protein panels for the early diagnosis of hepatocellular carcinoma;Nature Communications;2023-12-18

2. MDTips: a multimodal-data-based drug–target interaction prediction system fusing knowledge, gene expression profile, and structural data;Bioinformatics;2023-06-28

3. Proteomics-driven noninvasive screening of circulating serum protein panels for the early diagnosis of hepatocellular carcinoma;2023-04-25

4. A novel prognostic system combining carbonic anhydrase II and preoperative CA19‐9 for intrahepatic cholangiocarcinoma after curative resection;Cancer;2023-01-10

5. Advancements in Hepatocellular Carcinoma: Potential Preclinical Drugs and their Future;Current Pharmaceutical Design;2023-01